Free Trial

Theravance Biopharma (TBPH) Competitors

Theravance Biopharma logo
$11.22 -0.09 (-0.80%)
As of 04:00 PM Eastern

TBPH vs. NAMS, RXRX, BCRX, INDV, SPRY, CNTA, EVO, OCUL, GRDN, and AUPH

Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), BioCryst Pharmaceuticals (BCRX), Indivior (INDV), ARS Pharmaceuticals (SPRY), Centessa Pharmaceuticals (CNTA), Evotec (EVO), Ocular Therapeutix (OCUL), Guardian Pharmacy Services (GRDN), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "med - drugs" industry.

Theravance Biopharma vs. Its Competitors

Theravance Biopharma (NASDAQ:TBPH) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Theravance Biopharma has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500.

Theravance Biopharma has a net margin of -89.38% compared to NewAmsterdam Pharma's net margin of -397.45%. Theravance Biopharma's return on equity of -32.37% beat NewAmsterdam Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Theravance Biopharma-89.38% -32.37% -16.48%
NewAmsterdam Pharma -397.45%-37.34%-33.45%

Theravance Biopharma has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theravance Biopharma$64.38M8.71-$56.42M-$1.18-9.51
NewAmsterdam Pharma$47.14M47.68-$241.60M-$1.88-10.65

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 2 mentions for NewAmsterdam Pharma and 0 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.00 equaled NewAmsterdam Pharma'saverage media sentiment score.

Company Overall Sentiment
Theravance Biopharma Neutral
NewAmsterdam Pharma Neutral

Theravance Biopharma currently has a consensus target price of $16.60, suggesting a potential upside of 47.95%. NewAmsterdam Pharma has a consensus target price of $42.89, suggesting a potential upside of 114.23%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.67
NewAmsterdam Pharma
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by company insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Theravance Biopharma beats NewAmsterdam Pharma on 10 of the 16 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TBPH vs. The Competition

MetricTheravance BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$561M$2.37B$5.47B$8.92B
Dividend YieldN/A1.78%5.24%4.04%
P/E Ratio-9.518.9227.0520.14
Price / Sales8.71501.68380.7693.83
Price / CashN/A21.7726.2128.59
Price / Book3.144.528.005.58
Net Income-$56.42M$31.26M$3.16B$248.40M
7 Day Performance2.84%6.11%3.84%6.13%
1 Month Performance-0.27%5.75%3.04%7.78%
1 Year Performance26.92%1.24%34.26%20.95%

Theravance Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TBPH
Theravance Biopharma
1.4661 of 5 stars
$11.22
-0.8%
$16.60
+48.0%
+29.1%$561M$64.38M-9.51110
NAMS
NewAmsterdam Pharma
2.2597 of 5 stars
$18.11
-2.5%
$42.89
+136.8%
-2.7%$2.08B$45.56M-9.634Positive News
Analyst Upgrade
RXRX
Recursion Pharmaceuticals
1.9374 of 5 stars
$5.06
+0.6%
$7.00
+38.3%
-32.7%$2.04B$58.84M-2.86400Trending News
Analyst Forecast
BCRX
BioCryst Pharmaceuticals
4.4604 of 5 stars
$8.96
-4.3%
$16.89
+88.5%
+34.4%$1.96B$450.71M-34.46530
INDV
Indivior
2.6328 of 5 stars
$14.74
+5.7%
$17.00
+15.3%
+3.0%$1.92B$1.19B-47.551,051High Trading Volume
SPRY
ARS Pharmaceuticals
3.2379 of 5 stars
$17.45
-4.1%
$31.00
+77.7%
+87.8%$1.79B$89.15M-109.0690Positive News
High Trading Volume
CNTA
Centessa Pharmaceuticals
3.1689 of 5 stars
$13.14
+0.1%
$27.89
+112.2%
+55.8%$1.75B$6.85M-7.26200
EVO
Evotec
1.6999 of 5 stars
$4.20
+1.0%
$5.93
+41.3%
-21.1%$1.48B$862.40M0.004,827Positive News
OCUL
Ocular Therapeutix
3.9399 of 5 stars
$9.28
+0.7%
$17.33
+86.8%
+44.1%$1.47B$63.72M-8.07230Gap Up
GRDN
Guardian Pharmacy Services
1.3876 of 5 stars
$21.39
+0.0%
$25.67
+20.0%
N/A$1.35B$1.23B0.003,400High Trading Volume
AUPH
Aurinia Pharmaceuticals
2.5626 of 5 stars
$8.47
-2.0%
$11.50
+35.8%
+33.2%$1.17B$235.13M30.25300

Related Companies and Tools


This page (NASDAQ:TBPH) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners